Scalp folliculitis is a skin condition that occurs when the hair follicles on the scalp become inflamed. This results in pustules, whiteheads, or other pimple-like bumps on the scalp that can be ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." If you find yourself itching your head, you may have dry skin or irritating dandruff. While these are ...

Papulopustular rosacea is a subtype of rosacea, a common skin disorder characterized by facial redness and flushing. Papulopustular rosacea causes pus-filled blemishes called pustules and red, swollen ...

Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

An international panel of more than 30 experts has developed a consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP). The new definition, published in JAMA Dermatology, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Steven R. Feldman, ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

Generalized pustular psoriasis may be caused or triggered by various factors, including genetic mutations, infections, and certain medications. Generalized pustular psoriasis (GPP) is a severe form of ...

Mark G. Lebwohl, MD, and Maria Lopes, MD, MS, review the incidence and prevalence of generalized pustular psoriasis as well as direct and indirect costs associated with the disease. Ryan Haumschild, ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...